Cardarine (GW-501516): Benefits, Risks, and What the Research Shows

Cardarine, also called GW-501516 or endurobol, is a synthetic PPAR-delta agonist that changes how your body burns fuel, shifting muscle toward fat oxidation and slow-twitch fiber use. It’s not a SARM and not a hormone, despite how it gets sold. The cardarine benefits people chase are better endurance, fat loss, and improved cholesterol, but the strongest evidence sits in mice and the thing that ended human development is a cancer signal that has never gone away.

What cardarine actually is

Cardarine activates the peroxisome proliferator-activated receptor delta (PPARδ), a nuclear receptor that regulates genes controlling fatty acid transport and oxidation. That mechanism is the whole story. It isn’t an androgen, it doesn’t bind the androgen receptor, it doesn’t aromatize, and it doesn’t suppress your natural testosterone. The “SARM” label on most bottles is marketing, not chemistry.

DrugBank lists a half-life of roughly 20 hours, which supports once-daily oral dosing. Solid human pharmacokinetic data are thin, which the dataset flags directly. What is well documented is the mechanism and the animal pharmacology.

Cardarine benefits for cardio and endurance

This is the benefit with the most mechanistic backing. PPARδ activation does two things that directly help endurance: it increases fatty acid oxidation (so muscle burns fat more readily and spares glycogen), and it drives mitochondrial biogenesis. A 2004 study by Wang et al. in PLoS Biology showed cardarine converted fast-twitch muscle fibers into slow-twitch, fatigue-resistant fibers in mice, the same adaptation endurance training produces. That is why cardarine gets called an “exercise mimetic.”

The running-capacity gains in mice were dramatic. The catch is that these are rodent studies at research doses, and no controlled human endurance trial was ever completed before development stopped. The cardio benefit in people is real in the sense that the pathway is conserved across species, but the magnitude is extrapolated, not measured.

The human evidence: lipids and body composition

The strongest human data point is a Phase II trial published by Olson et al. in 2012. It gave 2.5, 5, or 10 mg daily for 12 weeks to 268 patients with low HDL cholesterol. The 10 mg dose raised HDL by about 17%, lowered LDL by 7%, and cut triglycerides by 17%. Particle-size analysis suggested the shifts were cardioprotective. Body weight rose about 1.3 kg, though the study didn’t separate lean from fat mass.

A 2008 study by Riserus et al. in moderately obese men found cardarine improved several metabolic markers over a short window. Phase I safety studies showed it was tolerated at 10 mg daily with no changes in liver enzymes, blood counts, or creatinine.

So the honest read on cardarine benefits for men and women is this: the mechanism is identical in both sexes because it isn’t sex-hormone driven. The lipid and metabolic effects are what the human data supports. The fat-loss and endurance reputation comes from animal data plus anecdote. There is no sex-specific clinical trial.

Cardarine benefits for men vs. women

Because cardarine isn’t androgenic, the men-versus-women question doesn’t work the way it does for steroids. There’s no virilization risk. Women don’t face voice deepening or clitoral changes from cardarine the way they do from AAS.

The practical difference is dosing. Clinical trials capped at 10 mg daily. Community protocols have used 10 to 20 mg per day for men and often half that for women, over 6 to 12 week runs, but those are self-reported patterns, not controlled data. Neither sex has a dedicated study. If there is a benefit that differs by sex, it hasn’t been measured.

The cancer risk: the fact that ended development

This is the part that matters most and gets dismissed most often. In 2009, GlaxoSmithKline withdrew cardarine’s new drug application after long-term carcinogenicity studies produced tumors in animals at every dose tested. Neoplasms appeared in the liver, bladder, thyroid, tongue, stomach, skin, testes, eyes, and uterus. This was reported by Newsholme et al. (mouse study) and Geiger et al. (rat study), both in The Toxicologist, 2009.

The lowest carcinogenic dose was 5 mg/kg per day, which scales to roughly 65 mg for an 80 kg human. Yes, the doses in some athletic protocols sit below that. No, that doesn’t make the risk disappear. Standard preclinical safety testing uses high doses precisely to surface carcinogenicity, and cardarine surfaced it in multiple organs across two species.

The athletic community often argues the studies used excessive doses. That argument doesn’t change the outcome. WADA issued a formal warning in 2013 about the “serious toxicities” found in preclinical testing. The drug has no approved human use anywhere.

Detection: cardarine is easily caught

Cardarine is WADA-prohibited, and the doping-control science is mature. A 2012 study by Sobolevsky and Dikunets in Drug Testing Analysis established that GW1516 sulfone metabolites are the recommended target analytes for urine screening. The detection window runs roughly 30 to 40 days after the last dose, assayed by LC-MS/MS.

WADA’s MRPL table (TD2022MRPL) sets the minimum required performance level for GW1516 and GW0742 metabolites (sulfoxide and sulfone) at 2 ng/mL. This isn’t a drug you can time around a test.

FAQ

What are the main cardarine benefits?

In animal studies: increased endurance, greater fat oxidation, fiber-type remodeling toward slow-twitch, and improved lipid profiles. In human trials (Olson 2012): HDL up about 17%, LDL down 7%, triglycerides down 17% at 10 mg daily. The endurance and fat-loss claims in people are mostly extrapolated from mice.

How long is cardarine detectable?

Roughly 30 to 40 days, via the GW1516 sulfone metabolites on LC-MS/MS (Sobolevsky and Dikunets, 2012). WADA’s MRPL for these metabolites is 2 ng/mL.

Why was cardarine discontinued?

In 2009, long-term animal carcinogenicity studies showed tumors at every dose tested, in multiple organs, in both mice and rats. GSK withdrew the drug. WADA issued a public warning in 2013.

Is cardarine a SARM?

No. It’s a PPARδ agonist with no androgen receptor activity. The “SARM” label is a marketing convention, not a pharmacological classification.

Does cardarine suppress testosterone?

No. It isn’t a hormone and doesn’t act on the androgen receptor or the HPTA axis. It doesn’t aromatize and doesn’t suppress endogenous testosterone.

Sources

• Olson EJ, Pearce GL, Jones NP, Sprecher DL. Lipid effects of PPARδ agonist GW501516 in subjects with low HDL cholesterol. Arterioscler Thromb Vasc Biol. 2012;32:2289-2294.
• Wang YX, et al. Regulation of muscle fiber type and running endurance by PPARδ. PLoS Biology. 2004;2(10):e294.
• Riserus U, et al. Activation of PPARδ reverses multiple metabolic abnormalities in moderately obese men. Diabetes. 2008;57(2):332-339.
• Newsholme SJ, et al. Mouse carcinogenicity study with GW501516, a PPARδ agonist. The Toxicologist. 2009;108(1).
• Geiger LE, et al. Rat carcinogenicity study with GW501516, a PPARδ agonist. The Toxicologist. 2009;108(1).
• Sobolevsky T, Dikunets M. Detection of GW1516 metabolites in human urine. Drug Testing and Analysis. 2012.
• World Anti-Doping Agency. TD2022MRPL: Minimum Required Performance Levels. wada-ama.org.
• DrugBank. GW-501516 (DB05416). go.drugbank.com.